The DOI matches its Crossref record.
Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor
Abstract
Myelodysplastic syndromes (MDS) are characterized by chronic refractory cytopenias resulting in increased risk of infection, bleeding, and conversion to acute leukemia. In an effort to improve these cytopenias we have treated 18 patients over a 6- to 8-week period with increasing daily subcutaneous doses of recombinant human granulocyte colony- stimulating factor (G-CSF). Sixteen patients responded with improvement in neutrophil counts. On cessation of treatment these counts returned to baseline values over a 2- to 4-week period. To maintain these improved blood counts 11 patients were treated with G-CSF for more prolonged periods. Ten patients again responded with an increase in total leukocyte counts (1.6- to 6.4-fold) and absolute neutrophil counts (ANC) (3.6- to 16.3-fold), with responses persisting for 3 to 16 months. A significantly decreased risk of developing bacterial infections was noted during periods with ANC greater than 1,500/mm3 as compared with periods of time with ANC less than 1,500/mm3. Two anemic patients had a greater than 20% rise in hematocrit over the study period, and 2 additional patients had a decrease in red blood cell transfusion requirements during G-CSF treatment. Bone marrow myeloid maturation improved in 7 of 9 maintenance phase patients. Three patients progressed to acute myeloid leukemia during treatment. The drug was generally well-tolerated and no severe toxicities were noted. These data demonstrated that G-CSF administered to MDS patients by daily subcutaneous administration was well-tolerated and effective in causing persistent improvement of the neutrophil levels and marrow myeloid maturation. These effects were associated with a decreased risk of infection and, in some patients, with decreased red blood cell transfusion requirements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
Ioannidis, J. P. A. (2005) · JAMA · doi:10.1001/jama.294.2.218 · Cited by 1,465
Granulocyte colony-stimulating factor and its receptor
Demetri, G., & Griffin, J. (1991) · Blood · doi:10.1182/blood.v78.11.2791.2791 · Cited by 1,064
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor
Wood, A. J. J., Lieschke, G. J., & Burgess, A. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207023270106 · Cited by 818
Filgrastim (r-metHuG-CSF): the first 10 years
Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G. (1996) · Blood · doi:10.1182/blood.v88.6.1907.bloodjournal8861907 · Cited by 599
Metadata
- Authors
- Negrin, R., Haeuber, D., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M., & Greenberg, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1990-07-01
- Volume
- 76
- Issue
- 1
- Pages
- 36-43
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2147530468
- Cited by
- 232
- References
- 0
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. https://app.cochat.ai/papers/10.1182/blood.v76.1.36.36
- The paper
- Negrin, R., Haeuber, D., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M., & Greenberg, P. (1990). Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. https://doi.org/10.1182/blood.v76.1.36.36
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.